Prevalence and cost of medication nonadherence in Parkinson's disease: Evidence from administrative claims data
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
We estimated the prevalence of medication nonadherence in Parkinson's disease (PD) and the association between treatment nonadherence and healthcare costs. Insurance claims from over 30 US health plans were analyzed. Inclusion criteria were as follows: PD diagnosis, ≥1 PD‐related prescription between 1/1/1997 and 12/31/2004, continuous health plan enrollment for ≥6 months before and ≥12 months after first PD prescription. Adherence, all‐cause healthcare utilization, and all‐cause costs were evaluated over 12 months post‐treatment initiation. Adherence was measured using the medication possession ratio (MPR), with MPR < 0.8 defining nonadherence. Among patients identified for inclusion (N = 3,119), 58% were male and mean age was 69 years. Mean MPR was 0.58 and 61% of patients were nonadherent. Unadjusted mean medical costs were significantly higher (P < 0.01) among nonadherers ($15,826) compared with adherers ($9,228), although nonadherers had lower prescription drug costs ($2,684 vs. $3,854; P < 0.05). After controlling for confounders in multivariable analyses, a large positive relationship between nonadherence and both medical and total healthcare costs remained (+$3,451, P < 0.0001 and +$2,383, P = 0.0053, respectively). Medication adherence in PD is suboptimal and nonadherence may be associated with increased healthcare costs despite offsets from reduced drug intake. Efforts to promote medication adherence in PD may lead to cost savings for managed care systems. © 2010 Movement Disorder Society
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pharmacotherapy to sustain the fully remitted state
Kennedy, S., McIntyre, R., Fallu, A., & Lam, R. (2002) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn.0245 · Cited by 56 · cited 1×
“Nonadherence with pharmacotherapy is a significant problem faced by medical practice because it reduces treatment benefits,(3,4) confounds the assessment of treatment effectiveness,(5) and may lead to poorer disease prognosis.(6,7) In addition to its clinical effects, medication nonadherence imposes a substantial fina…”
Background
Cited by
Economic impact of medication non-adherence by disease groups: a systematic review
Cutler, R. L., Fernandez-Llimos, F., Frommer, M., Benrimoj, C., & Garcia-Cardenas, V. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-016982 · Cited by 900
“The unadjusted total cost ranged from $10 988 to $52 023.(34) 37 71 Wei et al(71) further subgrouped patients into MPR adherence percentage categories and found that costs increased in all economic indicators (inpatient costs and outpatient costs) as adherence decreased, except for pharmacy costs which decreased with…”
BackgroundGrenard, J. L., Munjas, B. A., Adams, J. L., Suttorp, M., Maglione, M., McGlynn, E. A., & Gellad, W. F. (2011) · Journal of General Internal Medicine · doi:10.1007/s11606-011-1704-y · Cited by 635
Peter, I., Dubinsky, M., Bressman, S., Park, A., Lu, C., Chen, N., & Wang, A. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2018.0605 · Cited by 386
Rabelo, A. G., Neves, L. P., Paixão, A. P. S., Oliveira, F. H. M., de Souza, L. A. P. S., Vieira, M. F., Pereira, A. A., & Andrade, A. O. (2017) · Annals of Biomedical Engineering · doi:10.1007/s10439-017-1908-3 · Cited by 46
Metadata
- Authors
- Davis, K. L., Edin, H. M., & Allen, J. K.
- Venue
- Movement Disorders
- Publisher
- Wiley
- Published
- 2010-03-15
- Volume
- 25
- Issue
- 4
- Pages
- 474-480
- ISSN
- 0885-3185 (ISSN-L)
- 1531-8257
- OpenAlex
- W2005762357
- Cited by
- 92
- References
- 1
- FWCI
- 5.25
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prevalence and cost of medication nonadherence in Parkinson's disease: Evidence from administrative claims data. https://app.cochat.ai/papers/10.1002/mds.22999
- The paper
- Davis, K. L., Edin, H. M., & Allen, J. K. (2010). Prevalence and cost of medication nonadherence in Parkinson's disease: Evidence from administrative claims data. Movement Disorders. https://doi.org/10.1002/mds.22999
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.